Global Sanfilippo Syndrome Type A (MPS IIIA) Pipeline Insight, 2020 - Insights Into the Present Clinical Development Scenario and Growth Prospects Across the Market - ResearchAndMarkets.com

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Sanfilippo Syndrome Type A (MPS IIIA) market.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, July 3, 2020
Information
Tags: 
Pharmaceutical, Health, Clinical trials, Syndromes, Sanfilippo syndrome, Health, Sanfilippo, Hunter syndrome, Branches of biology, Medicine
Summary
Key Points: 
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Sanfilippo Syndrome Type A (MPS IIIA) market.
  • A detailed picture of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline landscape is provided, which includes the disease overview and Sanfilippo Syndrome Type A (MPS IIIA) treatment guidelines.
  • The assessment part of the report embraces in-depth Sanfilippo Syndrome Type A (MPS IIIA) commercial assessment and clinical assessment of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • The Sanfilippo Syndrome Type A (MPS IIIA) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Sanfilippo Syndrome Type A (MPS IIIA) across the complete product development cycle, including all clinical and nonclinical stages.


The "Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Sanfilippo Syndrome Type A (MPS IIIA) market. A detailed picture of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline landscape is provided, which includes the disease overview and Sanfilippo Syndrome Type A (MPS IIIA) treatment guidelines.

The assessment part of the report embraces in-depth Sanfilippo Syndrome Type A (MPS IIIA) commercial assessment and clinical assessment of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sanfilippo Syndrome Type A (MPS IIIA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Sanfilippo Syndrome Type A (MPS IIIA) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Sanfilippo Syndrome Type A (MPS IIIA) treatment.
  • Sanfilippo Syndrome Type A (MPS IIIA) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Sanfilippo Syndrome Type A (MPS IIIA) market.

Scope of the Report

  • The Sanfilippo Syndrome Type A (MPS IIIA) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Sanfilippo Syndrome Type A (MPS IIIA) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Sanfilippo Syndrome Type A (MPS IIIA) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Sanfilippo Syndrome Type A (MPS IIIA) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Sanfilippo Syndrome Type A (MPS IIIA).

Key Topics Covered

1. Report Introduction

2. Sanfilippo Syndrome Type A (MPS IIIA)

2.1. Overview

2.2. History

2.3. Sanfilippo Syndrome Type A (MPS IIIA) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Sanfilippo Syndrome Type A (MPS IIIA) Diagnosis

2.6.1. Diagnostic Guidelines

3. Sanfilippo Syndrome Type A (MPS IIIA) Current Treatment Patterns

3.1. Sanfilippo Syndrome Type A (MPS IIIA) Treatment Guidelines

4. Sanfilippo Syndrome Type A (MPS IIIA) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Sanfilippo Syndrome Type A (MPS IIIA) companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Sanfilippo Syndrome Type A (MPS IIIA) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Sanfilippo Syndrome Type A (MPS IIIA) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Sanfilippo Syndrome Type A (MPS IIIA) Late Stage Products (Phase-III)

7. Sanfilippo Syndrome Type A (MPS IIIA) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sanfilippo Syndrome Type A (MPS IIIA) Discontinued Products

13. Sanfilippo Syndrome Type A (MPS IIIA) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Sanfilippo Syndrome Type A (MPS IIIA) Key Companies

15. Sanfilippo Syndrome Type A (MPS IIIA) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Sanfilippo Syndrome Type A (MPS IIIA) Unmet Needs

18. Sanfilippo Syndrome Type A (MPS IIIA) Future Perspectives

19. Sanfilippo Syndrome Type A (MPS IIIA) Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Companies Mentioned

  • Swedish Orphan Biovitrum
  • BioMarin Pharmaceutical
  • LYSOGENE
  • Abeona Therapeutics, Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rqezex

Copyright: 
Copyright Business Wire 2020